These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25311239)

  • 1. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
    Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
    Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE-5 inhibitors: clinical points.
    Doumas M; Lazaridis A; Katsiki N; Athyros V
    Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
    Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
    Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
    Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
    Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
    Mostafa T
    Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
    Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
    Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database.
    DE Nunzio C; Nacchia A; Grimaldi MC; Turchi B; Rovesti L; Franco A; Guarnotta G; Voglino O; Mancini E; Baldassarri V; Lombardo R; Cicione A; Tubaro A
    Minerva Urol Nephrol; 2024 Apr; 76(2):203-209. PubMed ID: 38498298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of levitra on sustenance of erection (EROS): an open-label, prospective, multicenter, single-arm study to investigate erection duration measured by stopwatch with flexible dose vardenafil administered for 8 weeks in subjects with erectile dysfunction.
    Shin YS; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
    Int J Impot Res; 2015; 27(3):95-102. PubMed ID: 25471318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
    Sheweita SA; Wally M; Hassan M
    Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
    Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
    Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
    van Landingham SW; Singman EL
    Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
    Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
    Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord Injury.
    Ohl DA; Carlsson M; Stecher VJ; Rippon GA
    Sex Med Rev; 2017 Oct; 5(4):521-528. PubMed ID: 28341580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.